Biotech Values

[genisi]

Teva at risk launches

On Lotrel - Par's settlement with NVS is a significant positive for Teva, which has the only generic on the market (except for Sandoz's authorized).
On Protonix - Wyeth's preliminary injunction was rejected and Teva's obviousness arguments might even win the litigation but even if Teva loses, the risk is much lower than it seemed (probably single not treble damages).
Gemzar is a potential for at risk launch by Teva.